Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Cardiff Oncology (CRDF) over the last 14 years, with Q3 2025 value amounting to $25000.0.

  • Cardiff Oncology's Cash from Financing Activities fell 9966.34% to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $44.2 million, marking a year-over-year increase of 36096.75%. This contributed to the annual value of $53.8 million for FY2024, which is N/A changed from last year.
  • Cardiff Oncology's Cash from Financing Activities amounted to $25000.0 in Q3 2025, which was down 9966.34% from $3000.0 recorded in Q1 2025.
  • Over the past 5 years, Cardiff Oncology's Cash from Financing Activities peaked at $44.2 million during Q4 2024, and registered a low of $3000.0 during Q1 2025.
  • Its 4-year average for Cash from Financing Activities is $8.9 million, with a median of $1.7 million in 2021.
  • In the last 5 years, Cardiff Oncology's Cash from Financing Activities crashed by 1556.5% in 2021 and then plummeted by 9966.34% in 2025.
  • Over the past 4 years, Cardiff Oncology's Cash from Financing Activities (Quarter) stood at $15.0 million in 2021, then tumbled by 99.5% to $75000.0 in 2022, then skyrocketed by 58817.33% to $44.2 million in 2024, then tumbled by 99.94% to $25000.0 in 2025.
  • Its Cash from Financing Activities stands at $25000.0 for Q3 2025, versus $3000.0 for Q1 2025 and $44.2 million for Q4 2024.